NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win®...
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech Appoints Fai§al Miyara, Ph.D., as Chief Business Officer
IO Biotech Announces Acceptance of Abstract to be Presented
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
IO Biotech to Present at 44th Annual Cowen Health Care Conference
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
IO Biotech Announces 2023 Third Quarter Results